Researchers identify drug resistance factors for advanced prostate cancer
Researchers have identified critical genomic changes in response to abiraterone acetate/prednisone, a standard treatment option for men with progressive, incurable and castration-resistant prostate cancer.
Materials provided by Mayo Clinic. Original written by Colette Gallagher. Note: Content may be edited for style and length.
Source link aaaaa